Jazz Pharmaceuticals
JAZZ
486 hedge funds and large institutions have $8.82B invested in Jazz Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 73 funds opening new positions, 183 increasing their positions, 138 reducing their positions, and 47 closing their positions.
55% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 47
33% more repeat investments, than reductions
Existing positions increased: 183 | Existing positions reduced: 138
14% more capital invested
Capital invested by funds: $7.76B → $8.82B (+$1.06B)
4% more funds holding
Funds holding: 468 → 486 (+18)
3.61% less ownership
Funds ownership: 92.87% → 89.26% (-3.6%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
51% less call options, than puts
Call options by funds: $28.3M | Put options by funds: $58.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$92.1M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$60M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$49.5M |
| 4 |
LSV Asset Management
Chicago,
Illinois
|
+$43.2M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$34.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$202M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$96.7M |
| 3 |
JP Morgan Chase
New York
|
-$96.6M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$83.8M |
| 5 |
SC
Samlyn Capital
New York
|
-$61.8M |
JAZZ Hedge Fund Activity: Q4 2022 in Review
486 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2022, worth a combined $8.82B — up 14% from $7.76B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new JAZZ positions and 47 closed out — a net gain of 26 holders — while 183 added to existing stakes and 138 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $92.1M. The largest seller was Janus Henderson Group, cutting an estimated $202M.
- 486 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2022, up from 468 in Q3 2022.
- Funds reported $8.82B of Jazz Pharmaceuticals stock for Q4 2022, up 14% quarter-over-quarter.
- 73 funds opened new Jazz Pharmaceuticals positions in Q4 2022 and 47 closed out, a net change of +26 holders.
- The largest Jazz Pharmaceuticals buyer in Q4 2022 was Citadel Advisors, an estimated $92.1M added.
- The largest Jazz Pharmaceuticals seller in Q4 2022 was Janus Henderson Group, an estimated $202M sold.
Based on aggregated 13F filings for Q4 2022.